Stock ABIO ARCA BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ARCA biopharma, Inc.

Equities

ABIO

US00211Y5069

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
3.55 USD +4.72% Intraday chart for ARCA biopharma, Inc. +9.57% +108.82%
Apr. 25 ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 19 North American Morning Briefing : Stock Futures -2- DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
BU
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
AQ
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of ARCA Biopharma, Inc. - ABIO
PR
ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO
BU
Shareholder Alert: Ademi LLP investigates whether ARCA biopharma, Inc. has obtained a Fair Price in its transaction with Oruka
PR
ABIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ARCA Biopharma, Inc. Is Fair to Shareholders
BU
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
AQ
ARCA biopharma Announces 2023 Financial Results
AQ
ARCA biopharma Announces Third Quarter 2023 Financial Results
AQ
ARCA biopharma announces Second Quarter 2023 Financial Results
AQ
ARCA biopharma Announces Second Quarter 2023 Financial Results
AQ
ARCA biopharma : Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options - Form 8-K
PU
ARCA biopharma Announces First Quarter 2023 Financial Results
AQ
ARCA BIOPHARMA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
AQ
ARCA biopharma : Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options - Form 8-K
PU
ARCA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
AQ
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
AQ
ARCA BIOPHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
ARCA BIOPHARMA, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABIO Stock
  4. News ARCA biopharma, Inc.
  5. Press Releases